<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12205" href="/d/html/12205.html" rel="external">see "Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12712" href="/d/html/12712.html" rel="external">see "Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F161214"><span class="drugH1">Brand Names: US</span>
<ul>
<li>TDVax;</li>
<li>Tenivac</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F161226"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Bacterial)</li></ul></div>
<div class="block doa drugH1Div" id="F161216"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Td vaccines (eg, TDVax, Tenivac) are for use in patients ≥7 years of age; DT vaccines (generics) are for use in pediatric patients 6 weeks to &lt;7 years of age. Td vaccines contain less diphtheria toxoid than DT vaccines; the vaccines are not interchangeable.</p>
<p style="text-indent:-2em;margin-left:4em;">Whenever feasible, the same manufacturer should be used for all doses of the vaccination series; however, vaccination should not be deferred if a specific brand is not known or is not available. Doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2023]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3186cf6-f751-4742-9832-a3acba1abdd9">Booster immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Booster</b>
<b> immunization (Td [eg, TDVax, Tenivac]):</b> IM: 0.5 mL every 10 years (for routine booster in patients who have completed primary immunization series). The Advisory Committee on Immunization Practices (ACIP) prefers Tdap for use in some situations if no contraindications exist (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]); refer to Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine monograph for additional information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization (Td [eg, TDVax, Tenivac]):</b> IM: Patients previously not immunized should receive 2 primary doses of 0.5 mL each, given at an interval of at least 4 weeks; third (reinforcing) dose of 0.5 mL 6 to 12 months later. Patients not completely immunized (&lt;3 doses) should receive the remaining doses. For patients who have not received Tdap, at least one dose should be included as part of primary immunization (in place of one or more of the Td doses; preferably the first dose) (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c6747cb-b589-4543-865e-99012050feac">Tetanus prophylaxis in wound management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus prophylaxis in wound management (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]):</b> IM: Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated and the immunization status of the patient, including time from last tetanus-containing vaccine. Wound management includes use of tetanus toxoid and/or tetanus immune globulin (TIG) where indicated, wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose, even if they have a wound that is neither clean nor minor. See table.</p>
<table border="1" data-table-id="diptet" frame="border" rules="all">
<caption style="text-align:center;">
<b>Tetanus Prophylaxis in Wound Management</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2" valign="middle">
<p style="text-indent:0em;">History of tetanus immunization doses</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Clean, minor wounds</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">All other wounds<sup class="footnote-number">a</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Tetanus toxoid<sup class="footnote-number">b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">TIG</p></th>
<th align="center">
<p style="text-indent:0em;">Tetanus toxoid<sup class="footnote-number">b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">TIG</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>a</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>b</sup>Tetanus toxoid in this chart refers to a tetanus toxoid-containing vaccine. For children &lt;7 years of age, DTaP (DT, if pertussis vaccine contraindicated) is recommended. For children 7 to 10 years of age who are not fully immunized against pertussis, diphtheria, or tetanus, Tdap should be used (followed by completion of catch-up series). Tdap is preferred in patients ≥11 years of age if the patient has not previously been vaccinated with Tdap, if Tdap history is unknown, or if the patient is pregnant. In patients who have previously been vaccinated with Tdap, either Td or Tdap may be used.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>c</sup>Yes, if ≥10 years since last dose.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>d</sup>Yes, if ≥5 years since last dose.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>e</sup>For patients with HIV infection or severe immunodeficiency with contaminated wounds, TIG should be administered, regardless of history of tetanus immunization.</p></td></tr>
<tr>
<td align="left" colspan="5" valign="top">
<p style="text-indent:0em;">Abbreviations: <b>DT</b> = diphtheria and tetanus toxoids (formulation for &lt;7 years of age); <b>DTaP</b> = diphtheria and tetanus toxoids, and acellular pertussis (formulation for &lt;7 years of age; Daptacel, Infanrix); <b>Td</b> = diphtheria and tetanus toxoids (formulation for ≥7 years of age; TDVax, Tenivac); <b>Tdap</b> = diphtheria and tetanus toxoids, and acellular pertussis (Adacel or Boostrix [formulations for ≥7 years of age]); <b>TIG</b> = tetanus immune globulin.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Uncertain or &lt;3 doses</b></p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td>
<td align="center">
<p style="text-indent:0em;">No</p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>3 or more doses</b></p></td>
<td align="center">
<p style="text-indent:0em;">No<sup class="footnote-number">c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No</p></td>
<td align="center">
<p style="text-indent:0em;">No<sup class="footnote-number">d</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No<sup class="footnote-number">e</sup></p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991695"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989011"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F161217"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F161223"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12712" href="/d/html/12712.html" rel="external">see "Diphtheria and tetanus toxoid vaccines (Td [age ≥7 years]; DT [age &lt;7 years] discontinued by manufacturer): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> DT vaccines (generics) are for use in pediatric patients 6 weeks to &lt;7 years of age; Td vaccines (eg, TDVax, Tenivac) are for use in patients ≥7 years of age. Td vaccines contain less diphtheria toxoid than DT vaccines; the vaccines are not interchangeable. Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Whenever feasible, the same manufacturer should be used for all doses of the vaccination series; however, vaccination should not be deferred if a specific brand is not known or is not available. Doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2023]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization: Note:</b> Only use DT in place of DTaP in patients with contraindication to pertussis-containing vaccines.</p>
<p style="text-indent:-2em;margin-left:4em;">CDC (ACIP) recommendations (CDC/ACIP [Liang 2018]): Infants and Children 6 weeks through &lt;7 years: <b>Note:</b> Preterm infants should be vaccinated according to their chronological age from birth:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric formulation (DT): IM: 0.5 mL per dose for a total of 5 doses administered as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Three doses (primary series), usually given at 2-, 4-, and 6 months of age; may be given as early as 6 weeks of age and repeated every 4 to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Fourth dose (first booster): Given at ~15 to 18 months of age, but at least 6 months after third dose. The fourth dose may be given as early as 12 months of age, but at least 6 months must have elapsed between the third dose and the fourth dose. The fourth dose does not need to be repeated if inadvertently administered at least 4 months after the third dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Fifth dose (second booster): Given at 4 to 6 years of age, prior to starting school or kindergarten; if the fourth dose is given at ≥4 years of age, the fifth dose may be omitted.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CDC (ACIP) Recommendations (CDC/ACIP [Liang 2018]): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children who start primary immunization series ≥4 months of age through 6 years (prior to seventh birthday): Pediatric formulation (DT) for those with contraindications to pertussis-containing vaccines: IM: 0.5 mL per dose for a total of 4 to 5 doses based on previous vaccination doses received and ages.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥7 years and Adolescents not fully or never vaccinated against diphtheria or tetanus, or whose vaccination status is not known, but has contraindications to pertussis-containing vaccines or has received sufficient pertussis doses: Adult formulation (Td [eg, TDVax, Tenivac]): IM: 0.5 mL per dose for a total of 3 to 4 doses based on number of previous vaccination doses, intervals, and patient age.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3186cf6-f751-4742-9832-a3acba1abdd9">Booster immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Booster immunization:</b> For routine booster in patients who have completed primary immunization series. The ACIP prefers Tdap for use in some situations if no contraindications exist; refer to Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine monograph for additional information (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥11 years and Adolescents ≤18 years: Td (eg, TDVax, Tenivac): IM: 0.5 mL as a single dose; preferred age for booster is 11 to 12 years of age. If not contraindicated, Tdap is the preferred agent for this dose. Booster doses of either Td or Tdap are recommended every 10 years thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If Tdap was given either inadvertently or as part of catch-up dosing at 7 to 9 years of age, this should not be counted as the adolescent booster dose. The child should still receive Tdap between ages 11 to 12 years. Regular tetanus boosters with either Tdap or Td should be administered every 10 years throughout life (CDC/ACIP [Havers 2020]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c6747cb-b589-4543-865e-99012050feac">Tetanus prophylaxis in wound management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus prophylaxis in wound management</b> (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]): Infants, Children, and Adolescents: Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated, and the immunization status of the patient, including time from last tetanus-containing vaccine. Wound management includes use of tetanus toxoid and/or tetanus immune globulin (TIG) where indicated, wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Tetanus Prophylaxis Wound Management</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">History of Tetanus Immunization (Doses)</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Clean, Minor Wounds</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">All Other Wounds<sup>1</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>1</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>2</sup>Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old, DTaP (DT, if pertussis vaccine contraindicated) is recommended. For children 7 to 10 years who are not fully immunized against pertussis, diphtheria, or tetanus, Tdap should be used (followed by completion of catch-up series). Tdap is preferred in patients ≥11 years of age if the patient has not previously been vaccinated with Tdap, if Tdap history is unknown, or if the patient is pregnant. In patients who have previously been vaccinated with Tdap, either Td or Tdap may be used.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>3</sup>Yes, if ≥10 years since last dose.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>4</sup>Yes, if ≥ 5 years since last dose.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>5</sup>For patients with HIV infection or severe immunodeficiency with contaminated wounds, TIG should be administered, regardless of history of tetanus immunization.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">Abbreviations: <b>DT</b> = Diphtheria and Tetanus Toxoids (formulation for age &lt;7 years); <b>DTaP</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &lt;7 years; Daptacel, Infanrix); <b>Td</b> = Diphtheria and Tetanus Toxoids (formulation for age ≥7 years; TDVax, Tenivac); <b>Tdap</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel or Boostrix [formulations for age ≥7 years]); <b>TIG</b> = Tetanus Immune Globulin</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">Tetanus toxoid <sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">TIG</p></td>
<td align="center">
<p style="text-indent:0em;">Tetanus toxoid <sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">TIG</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Uncertain or &lt;3 doses</p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td>
<td align="center">
<p style="text-indent:0em;">No</p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td>
<td align="center">
<p style="text-indent:0em;">Yes</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3 or more doses</p></td>
<td align="center">
<p style="text-indent:0em;">No<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No</p></td>
<td align="center">
<p style="text-indent:0em;">No<sup>4</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No<sup>5</sup></p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51094027"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51094028"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F161196"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">
<b>All serious adverse reactions must be reported to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Fesub%2Findex&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD%2B0my2cUJQ&amp;TOPIC_ID=9372" target="_blank">https://vaers.hhs.gov/esub/index</a>.</b> In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages noted within 2 weeks following booster dose of Decavac in persons ≥11 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (34% to 40%), fatigue (21% to 27%), body pain (≤19% to 30%), myasthenia (≤19% to 30%), chills (7% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (8% to 12%), diarrhea (10% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (63% to 71%), erythema at injection site (20% to 22%), swelling at injection site (17% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤7% to 12%), joint swelling (≤7% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Adenopathy (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Anaphylaxis, arthralgia, dizziness, hypersensitivity reaction (includes angioedema, skin rash, urticaria), injection site reaction (includes cellulitis, induration at injection site, injection site nodule, warm sensation at injection site), limb pain, lymphadenopathy, musculoskeletal stiffness, myalgia, pain, paresthesia, peripheral edema, seizure, syncope, weakness</p></div>
<div class="block coi drugH1Div" id="F161207"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to diphtheria, tetanus toxoid, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F161194"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Arthus-type hypersensitivity: Patients with a history of severe local reaction (Arthus-type) following a previous diphtheria toxoid or tetanus toxoid-containing vaccine dose should not be given further routine or emergency doses of Td unless ≥10 years since most recent dose, even if using for wound management with wounds that are not clean or minor; these patients generally have high serum antitoxin levels (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescent and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome: Use with caution if Guillain-Barré syndrome occurred within 6 weeks of prior tetanus toxoid-containing vaccine (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric dosage form (DT) should only be used in patients 6 weeks to ≤6 years of age. Td should be administered to children ≥7 years of age. Apnea has occurred following IM vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• DT confused with Td: Do not confuse pediatric diphtheria and tetanus (DT) with adult tetanus and diphtheria (Td).</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some products may contain natural latex/natural rubber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thimerosal: Some products may contain thimerosal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878429"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Diphtheria and tetanus toxoid is available in two formulations which contain different amounts of the diphtheria toxoid; DT or "pediatric" formulation has twice the diphtheria toxoid as Td or "adult" toxoid; use of DT in children &gt;7 years and adults is associated with more severe adverse reactions to the diphtheria toxoid than in infants and younger children. </p></div>
<div class="block prod-avail drugH1Div" id="F58224897"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Sanofi Pasteur discontinued production and distribution of Diphtheria and Tetanus Toxoids Adsorbed (DT) (diphtheria 25 Lf and tetanus 5 Lf per 0.5 mL) and is withdrawing its licenses in all countries. The last lot was manufactured in October 2020 with an expiry date of April 2023.</p></div>
<div class="block dosfc drugH1Div" id="F55756546"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Td vaccines (eg, TDVax, Tenivac) are for use in patients ≥7 years of age; DT vaccines (generics) are for use in pediatric patients 6 weeks to &lt;7 years of age. Td vaccines contain less diphtheria toxoid than DT vaccines; the vaccines are not interchangeable (CDC/ACIP [Havers 2020]).</p></div>
<div class="block foc drugH1Div" id="F161202"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tenivac: Diphtheria 2 Lf and tetanus 5 Lf per 0.5 mL (0.5 mL) [latex free; contains formaldehyde solution]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tenivac: Diphtheria 2 Lf and tetanus 5 Lf per 0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TDVax: Diphtheria 2 Lf and tetanus 2 Lf per 0.5 mL (0.5 mL) [contains aluminum phosphate, formaldehyde solution, thimerosal (thiomersal)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Diphtheria 2 Lf and tetanus 2 Lf per 0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Diphtheria 25 Lf and tetanus 5 Lf per 0.5 mL (0.5 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F161191"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323114"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Tenivac Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5-2 lfu (per 0.5 mL): $44.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (TDVax Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2 lf/0.5 mL (per 0.5 mL): $33.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Tetanus-Diphtheria Toxoids Td Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2 lf/0.5 mL (per 0.5 mL): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54799453"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Diphtheria 2 Lf and tetanus 5 Lf per 0.5 mL (0.5 mL)</p></div>
<div class="block adm drugH1Div" id="F161205"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For IM administration only; not for IV or SubQ administration. Prior to use, shake suspension well. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (ACIP [Kroger 2023]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:4em;">Td (eg, TDVax, Tenivac): Administer in the deltoid muscle; do not inject in the gluteal area. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2023]).</p></div>
<div class="block admp drugH1Div" id="F52612586"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Prior to use, shake suspension well; not for IV or SubQ administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2023]). To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (ACIP [Kroger 2023]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, vaccine information statement (VIS) edition date and date provided, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:4em;">DT: Administer IM in either the anterolateral aspect of the thigh or the deltoid muscle; do not inject in the gluteal area. If administering in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Td (eg, TDVax, Tenivac): Administer IM in the deltoid muscle; do not inject in the gluteal area. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2023]).</p></div>
<div class="block meg drugH1Div" id="F25734149"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the United States, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Ftd.html&amp;token=zJIVwBkqWiLAAtIOP%2Bk5yT3GejjvtqyPnfoyFqVZ7hCXSSGoN9E7jdetksW1GBrfwtlrxVVMVFSy8fGFZz22%2BA%3D%3D&amp;TOPIC_ID=9372" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/td.html</a>.</p></div>
<div class="block use drugH1Div" id="F161203"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diphtheria and tetanus disease prevention:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Diphtheria and tetanus toxoids adsorbed pediatric formulation (DT): Infants ≥6 weeks of age and children through 6 years of age: Active immunization against diphtheria and tetanus when pertussis vaccine is contraindicated; has also been used for tetanus prophylaxis in wound management.</p>
<p style="text-indent:-2em;margin-left:2em;">Tetanus and diphtheria toxoids adsorbed adult formulation (Td) (eg, TDVax, Tenivac): Children ≥7 years of age, adolescents, and adults: Active immunization against diphtheria and tetanus; tetanus prophylaxis in wound management.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for the following (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]):</p>
<p style="text-indent:-2em;margin-left:4em;">• For primary immunization against diphtheria and tetanus in infants and children 6 weeks to &lt;7 years of age in whom pertussis vaccine is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Children ≥7 years of age, adolescents, and adults should receive a booster dose of Td or Tdap every 10 years.</p>
<p style="text-indent:-2em;margin-left:4em;">• Children ≥7 years of age, adolescents, and adults: For wound management to prevent tetanus in patients with unknown or &lt;3 doses of previous tetanus vaccine, or who have not received a tetanus-containing vaccine recently (ie, 10 years for clean and minor wounds; 5 years for all other wounds). Tetanus immune globulin is also recommended for some wounds. Tdap is preferred over Td in persons ≥11 years of age who have not previously received Tdap, whose vaccination status is not known, or who are pregnant.</p>
<p style="text-indent:-2em;margin-left:4em;">• For patients who have recovered from tetanus or diphtheria infection: Because tetanus or diphtheria infection does not confer life-long immunity, active vaccination should be initiated at the time of recovery from the illness (according to the schedule). If the primary tetanus vaccination series has been completed, then a booster dose should be administered as soon as feasible during convalescence. Persons with unknown or uncertain previous tetanus vaccination histories should begin the 3-dose tetanus and diphtheria toxoids vaccination series.</p></div>
<div class="block mst drugH1Div" id="F7913819"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tetanus and Diphtheria and Toxoids (Td) may be confused with tuberculin purified protein derivative (PPD)</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric diphtheria and tetanus (DT) may be confused with adult tetanus and diphtheria (Td)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299214"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F161197"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meningococcal (Groups A / C / Y and W-135) Conjugate Vaccine: Tetanus Toxoids Vaccines may diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Conjugate Vaccine.  Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) conjugate vaccine (Nimenrix brand) either together with, or at least one month before, a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F161210"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nonlive bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2023]). Diphtheria toxoid and tetanus toxoid vaccines may be used during pregnancy (CDC/ACIP [Liang 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends a single Tdap vaccination during each pregnancy; ideally early in the period between 27 and 36 weeks' gestation to maximize passive antibody transfer to the fetus. Pregnant females who are not immunized or are only partially immunized should complete the primary series with Td or Tdap. Tetanus immune globulin and a tetanus toxoid containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant females; the use of a tetanus-toxoid containing vaccine during pregnancy (with preference given to Tdap) is recommended for wound management if ≥5 years have passed since the last Td vaccination (CDC/ACIP [Havers 2020]); CDC/ACIP [Liang 2018]).</p></div>
<div class="block brc drugH1Div" id="F12740779"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding following immunization should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of vaccination to the mother. Nonlive vaccines have not been shown to affect the safety of the breastfed infant or mother (ACIP [Kroger 2023]). Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2023]). Advisory Committee on Immunization Practices recommends that if Tdap was not administered during pregnancy, it should be administered during the immediate postpartum period to those with no history of Tdap; women who are not immunized or are only partially immunized should complete the primary series with Td or Tdap (CDC/ACIP [Havers 2020]; CDC/ACIP [Liang 2018]).</p></div>
<div class="block mop drugH1Div" id="F6839267"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F25306220"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Promotes active immunity to diphtheria and tetanus by inducing production of specific antibodies. </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038602"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">D.T. Vax Ads</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vacuna doble biol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Diphteria tetanus anatoxal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adt booster | Adt vaccine | Cdt</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Diftet | Tetadif</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vacina adsorvida difteria e tetano adulto (dT) | Vacina adsorvida difteria e tetano infantil (dT)</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ditanrix | Dt pediatric</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">BE Td | Diphtheria and tetanus vaccine adsorbed (pediatric) | Diphtheria and Tetanus vaccine adsorbed for adults and adolescents</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(CU)</span> <span class="country">Cuba</span><span class="countrySeparator">: </span><span class="drugName">Duple | Va diftet</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dt impfstoff fuer kinder | Td impfstoff | Td impfstoff merieux</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Diftet | Dt vax | Tetadif</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">D.T. vaccine | D.T.vax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal tedi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">BE Td</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ditebooster | Kaksoisrokote | Tetanus d rokote</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dt vax | Imovax d.t. adult | Imovax dt adult</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dip tet | Dip tet ads</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Di te anatoxal | Dt vax | Imovax dt | Tetadif</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adsorbed DT Vaccine | Bio td</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diphtheria, Tetanus Adsorbed Vaccine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">BE Td | Diphtheria and tetanus vaccine adsorbed (paediatric) | Diphtheria and tetanus vaccine adsorbed (pediatric) | Diphtheria and Tetanus vaccine adsorbed for adults and adolescents | Dt-int | Dual antigen | Sii Td Vac</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te | Ditanrix | H adiftetal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Diphtheria and tetanus vaccine adsorbed</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ditebooster | Dt vax | Td vaccine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dtvax | Tetadif</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Toxoides tetanico y difterico td adulto</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adsorbed dt vaccin | Di te anatoxal | Dt vax | Dual antigen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ditebooster</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adt vaccine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Di te anatoxal | Dif tet all</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Di te anatoxal | Diphtheria and tetanus vaccine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Decavac | Diphtheria and tetanus toxoids adsorbed</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal di te</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Di te anatoxal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Adsorbed DT Vaccine | Adsorbed td vaccine | Bio td | Di te anatoxal | Dif tet all | Dt vax | Td vax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dif tet all | Diftet | Diphtheria and Tetanus vaccine adsorbed for adults and adolescents</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anatoxal adulti | Tetadif</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diftet dt vaccine | Diphtheria and tetanus vaccine | Diphtheria and tetanus vaccine adsorbed (pediatric)</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Diphtheria and tetanus vaccine | Diphtheria and tetanus vaccine adsorbed (pediatric)</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dt vax</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Diphtheria and tetanus vaccine adsorbed (pedi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16557217">
<a name="16557217"></a>Broder KR, Cortese MM, Iskander JK, et al. Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-3):1-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/16557217/pubmed" id="16557217" target="_blank">16557217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23425962">
<a name="23425962"></a>Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(7):131-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/23425962/pubmed" id="23425962" target="_blank">23425962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18668022">
<a name="18668022"></a>Chapman LE, Sullivent EE, Grohskopf LA, et al; Centers for Disease Control and Prevention (CDC). Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events—United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). <i>MMWR Recomm Rep</i>. 2008;57(RR-6):1-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/18668022/pubmed" id="18668022" target="_blank">18668022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Diphtheria and Tetanus Toxoids Adsorbed [prescribing information]. Swiftwater, PA: Sanofi-Pasteur Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31971933">
<a name="31971933"></a>Havers FP, Moro PL, Hunter P, Hariri S, Bernstein H. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2019. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(3):77-83. doi:10.15585/mmwr.mm6903a5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/31971933/pubmed" id="31971933" target="_blank">31971933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182599">
<a name="28182599"></a>Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/28182599/pubmed" id="28182599" target="_blank">28182599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17167397">
<a name="17167397"></a>Kretsomger K, Broder K, Cortese MM, et al. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. <i>MMWR Recomm Rep</i>. 2006;55(RR-17):1-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/17167397/pubmed" id="17167397" target="_blank">17167397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29702631">
<a name="29702631"></a>Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2018;67(2):1-44. doi:10.15585/mmwr.rr6702a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/29702631/pubmed" id="29702631" target="_blank">29702631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29420458">
<a name="29420458"></a>Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018. <i>MMWR Morb Mortal Wkly Rep</i>. 2018;67(5):156-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/29420458/pubmed" id="29420458" target="_blank">29420458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphtheria-and-tetanus-toxoid-vaccines-td-age-7-years-dt-age-less-than7-years-discontinued-by-manufacturer-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  TDVAX (tetanus and diphtheria toxoids adsorbed) [prescribing information]. Los Angeles, CA: Grifols USA, LLC; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tenivac.1">
<a name="Tenivac.1"></a>Tenivac (tetanus and diphtheria toxoids adsorbed) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; received January 2023.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 9372 Version 210.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
